Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04650074
Other study ID # 69HCL18_0996
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date November 5, 2021
Est. completion date January 12, 2024

Study information

Verified date May 2024
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Complex Regional Pain Syndrome type 1 (CRPS1) is a disabling pain syndrome. Its definitive treatment has not been established and the results of current treatments are often unsatisfactory. The prognosis is difficult to establish because the vast majority of CRPS regresses within a few weeks. However, some forms are hyperalgesic with a major chronic painful picture, very debilitating and responding poorly to treatments with possible permanent sequelae. The management of CRPS remains difficult and unsatisfactory and is symptomatic, multidimensional and multidisciplinary involving medical, paramedical and socio-professional workers. The priority therapeutic objectives are analgesia, maintenance or gain of joint range and maintenance or restoration of motor functions. This treatment is not the subject of a consensus and its implementation is sometimes the responsibility of specialized centers such as "pain relief" centers or even Physical Medicine and Rehabilitation (MPR) structures. Previous studies using ketamine as a treatment for CRPS1 show encouraging results with a decrease in neuropathic pain. Ketamine is a low dose pain reliever. Ketamine has been studied as an adjuvant for the treatment of chronic pain, particularly neuropathic pain. The results suggest that ketamine decreases pain intensity and reduces opioid reliance when used as an adjunct to chronic and acute pain. Ketamine is believed to have a greater analgesic effect in patients with CRPS1 compared to other chronic pain syndromes. In these studies, ketamine was used intravenously, subcutaneously, orally, intranasally, or topically. Mesotherapy allows microdose local treatment to be carried out limiting side effects, ensuring compliance and easy to implement. The injected solutions often contain a local anesthetic (procaine or lidocaine). It allows better local tolerance from the start of treatment. In addition, through its vasodilator effect on the microcirculation, it increases the effectiveness and tolerance of other injected products. There are no studies using ketamine administrated by mesotherapy. Based on the scientific literature, there are good reasons to believe that this treatment could be effective on the neuropathic pain of CRPS1 and well tolerated.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date January 12, 2024
Est. primary completion date January 12, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male / female aged =18 years, - Patient suffering from Complex Regional Pain Syndrome Type 1 (CRPS1), according to the Budapest criteria, with a neuropathic component limited to the lower or upper limbs diagnosed by the Neuropathic pain DN4 Questionnaire - Patient having undergone a three-stage dynamic bone scan less than 3 months old : vascular, tissue, bone, showing diffuse and extensive hyperfixation in the area suspected of CRPS1, - Negative urinary pregnancy test in women of childbearing age, - VAS (Visual Analogue Scale) > 50mm (on a scale of 0 to 100 mm) at inclusion, - Patients affiliated to the French social security system, - Writing informed consent obtained. Exclusion Criteria: - Patient with the following medical history or ongoing pathologies: epilepsy, hypertension (> 180mm / 100mm Hg), unbalanced coronary artery disease, recent myocardial infarction (MDI) (less than 12 months), porphyria, hyperthyroidism, known Behçet's disease, known blood crass disorder or PT (Prothrombin Time) <20%, known psychiatric disorders, known septic osteoarticular disease, - Patient with HIV ((Human Immunodeficiency Viruses) infection, immunosuppression and / or immunosuppressive treatment - Severe heart failure, - History of severe allergy (angioedema), - Known allergies to Cr and Zn, - Current skin infection, - Skin lesion next to the injection area - Phobia of injections, - Known hypersensitivity to ketamine hydrochloride or chlorobutanol, - Known hypersensitivity to lidocaine hydrochloride or to amide-linked local anesthetics, - Pregnant or breastfeeding woman - Patient under protective measure (safeguard measure, curatorship, guardianship) or deprived of liberty.

Study Design


Intervention

Drug:
LIDOCAINE 20 mg
4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%). Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one: 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle, 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute.
LIDOCAINE 20 mg + KETAMINE 20 mg
4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%). Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one: 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle, 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute.
LIDOCAINE 20 mg + KETAMINE 40 mg
4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%). Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one: 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle, 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute

Locations

Country Name City State
France Department of orthopedic surgery and trauma emergencies of the lower limb, Edouard Herriot Hospital, Hospices Civils de Lyon Lyon

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analogue Scale (VAS) score Pain measured by VAS (Visual Analogue Scale) On day 0 (inclusion) and day 56 (end of patient follow-up)
Secondary Evolution of the Visual Analogue Scale score The VAS (Visual Analogue Scale) score will be assessed at inclusion, before each mesotherapy session, and at the end of the patient follow-up On day 0 (inclusion), on day 1, day 7, day 14 and day 28 (mesotherapy sessions), and on day 56 (end of patient follow-up)
Secondary Neuropathic Pain Symptom Inventory (NPSI) self-questionnaire score The Neuropathic pain will be assessed using the NPSI (Neuropathic Pain Symptom Inventory self-questionnaire) at inclusion, before each mesotherapy session, and at the patients withdrawal. On day 0 (inclusion), on day 1, day 7, day 14 and day 28 (mesotherapy sessions), and on day 56 (end of the patient follow-up)
Secondary Brief Pain Inventory (BPI) self-questionnaire score The main dimensions of pain (i.e. intensity, functional disability, social and family repercussions as well as the level of psychological distress) will be assessed using the BPI (Brief Pain Inventory self-questionnaire) at inclusion and at the patients withdrawal. On day 0 (inclusion) and on day 56 (end of patient follouw-up)
Secondary Relevant adverse events The relevant adverse events (AEs), as well as the average of the highest grades of the relevant adverse events, will be collected during the patient follow-up, in particular after each mesotherapy session. The physician will ask the patient at each of the visits and will report any adverse event (AE). The nature and intensity of the AE will be assessed according to the Common Terminology Criteria for Adverse Events grid (CTCAE version 5.0). Relevant adverse events (AEs at least possibly related to treatment or mesotherapy) will be considered. Until day 56 (end of patient follow-up)
Secondary Concomitant consumption of analgesics The consumption of other analgesics concomitant with the treatment will be recorded Until day 56 (end of patient follow-up)
Secondary EQ-5D-5L (EuroQol health states) questionnaire score The quality of life will be assessed using the EQ-5D-5L questionnaire (EuroQol health states) On day 1 (inclusion) and on day 56 (end of patient follow-up)
Secondary Visual Analogue Scale and Adverse Events grades (Benefit / risk balance) To simultaneously compare the VAS (Visual Analogue Scale) and the relevant adverse events (AE) grades between groups.
This benefit-risk balance will be estimate in a hierarchical fashion using the method of pairwise comparisons. The VAS will be used as the first endpoint (benefit) and the highest grade of AE in a given patient as the second endpoint (risk). No clinical relevance threshold will be specified for the two criteria for the primary analysis, but they will then be added as a sensitivity analysis.
Until day 56 (end of patient follow-up)
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Completed NCT05235191 - Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Not yet recruiting NCT05949554 - Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
Withdrawn NCT05052645 - Ear Acupuncture for Neuropathic Pain N/A
Completed NCT02824588 - Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain N/A
Completed NCT02866396 - Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
Completed NCT02930551 - Neuromas as the Cause of Pain N/A
Active, not recruiting NCT02560545 - Cannabinoids Effects on the Pain Modulation System N/A
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Not yet recruiting NCT02246517 - The Effect of N2O on Chronic Neuropathic Pain Patients Phase 0
Completed NCT02099890 - The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Phase 3
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Completed NCT01884662 - Virtual Walking for Neuropathic Pain in Spinal Cord Injury N/A
Completed NCT01718821 - Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients N/A
Completed NCT01669967 - The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin N/A
Completed NCT01201317 - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy Phase 2
Completed NCT01207596 - Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain Phase 4